Use of hydrofluoroalkane beclomethasone dipropionate (HFA-BDP) extrafine aerosol in optimising the management of allergic bronchopulmonary aspergillosis (ABPA)

J. M. FitzGerald (Vancouver, Canada)

Source: Annual Congress 2003 - Asthma: inhaled therapy; allergic bronchopulmonary aspergillosis
Session: "Asthma: inhaled therapy; allergic bronchopulmonary aspergillosis"
Session type: Thematic Poster Session
Number: 1581
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. M. FitzGerald (Vancouver, Canada). Use of hydrofluoroalkane beclomethasone dipropionate (HFA-BDP) extrafine aerosol in optimising the management of allergic bronchopulmonary aspergillosis (ABPA). Eur Respir J 2003; 22: Suppl. 45, 1581

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
HFA beclomethasone dipropionate (HFA-BDP) extrafine aerosol and formoterol in optimizing the management of bronchial asthma at children
Source: Eur Respir J 2005; 26: Suppl. 49, 159s
Year: 2005

Effects of the changing from chlorofluorocarbon (CFC)- beclomethasone dipropionate (BDP) to hydrofluoroalkane (HFA)-BDP on pulmonary function in asthmatic children
Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma
Year: 2007


Comparison of a new extrafine beclomethasone dipropionate HFA134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 206s
Year: 2006

A pharmaco-epidemiological audit of beclomethasone dipropionate extrafine aerosol in patients with asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 471s
Year: 2002

A comparison of the efficacy of beclomethasone dipropionate (BDP) and fluticasone propionate (FP) aqueous nasal spray on symptoms and quality of life in perennial allergic rhinitis
Source: Eur Respir J 2003; 22: Suppl. 45, 110s
Year: 2003

Long-term benefits of switching to hydrofluoroalkane beclomethasone dipropionate extrafine aerosol
Source: Eur Respir J 2001; 18: Suppl. 33, 331s
Year: 2001

Acceptability and efficacy of beclomethasone dipropionate (Béclojet HFA®) and fluticasone dipropionate (Flixotide HFA®, FDP) associated with the Volumatic® spacer in adults with mild to moderate persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 473s
Year: 2003

Nebulized beclomethasone dipropionate is as effective and as well tolerated than nebulized budesonide to prevent asthma exacerbations in infants
Source: Eur Respir J 2001; 18: Suppl. 33, 122s
Year: 2001

QVAR pMDI is more cost effective than CFC-beclometasone dipropionate (BDP) pMDI in a real-life asthmatic population initiating ICS
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

HFA vs CFC beclomethasone dipropionate – comparative effectiveness in asthma management
Source: Eur Respir J 2006; 28: Suppl. 50, 498s
Year: 2006

Therapeutic equivalence of beclomethasone dipropionate/formoterol administered via NEXTTM DPI with beclomethasone dipropionate/formoterol administered via HFA pMDI in adult asthmatic patients
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Clinical efficacy of seretide and beclomethasone dipropionate in patients with corticosteroid-dependent bronchial asthma and quality of life
Source: Eur Respir J 2004; 24: Suppl. 48, 285s
Year: 2004

Salmeterol and beclomethasone dipropionate versus higher dose beclomethasone dipropionate in asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Inhalation of beclomethason dipropionate spray compared with theophilline as primary treatment for chronic mild-to-moderate asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 42s
Year: 2002

Protective effect of inhaled beclomethasone dipropionate (BDP) in asthmatic patients with exercise-induced bronchoconstriction (EIB)
Source: Eur Respir J 2002; 20: Suppl. 38, 306s
Year: 2002

Evaluation of fluticasone (flixonase) nasal spray versus beclomethasone (beconase) nasal spray in the treatment of allergic rhinitis
Source: Eur Respir J 2004; 24: Suppl. 48, 124s
Year: 2004

Comparison of a new HFA 134a-formulated budesonide pMDI with a standard CFC-formulated budesonide pMDI in children with persistent asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 160s
Year: 2005

QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

Utility of inhaled corticosteroids (fluticasone/formoterol) by pressurized metered-dose inhaler for the early management of acute exacerbations of asthma
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010